Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic

Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair

(2011) Arun Gupta et al.   CELL CYCLE

The Mechanism of Double-Strand DNA Break Repair by the Nonhomologous DNA End-Joining Pathway

(2010) Michael R. Lieber   Annual Review of Biochemistry

Defective Mismatch Repair, Microsatellite Mutation Bias, and Variability in Clinical Cancer Phenotypes

(2010) S. N. Shah et al.   CANCER RESEARCH

Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination-Defective Cells

(2010) P. Gottipati et al.   CANCER RESEARCH

PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors

(2010) B. McEllin et al.   CANCER RESEARCH

BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair

(2010) P. J. O'Donovan et al.   CARCINOGENESIS

Homologous recombination in cancer development, treatment and development of drug resistance

(2010) T. Helleday   CARCINOGENESIS

53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks

(2010) Samuel F. Bunting et al.   CELL

Monitoring Drug-Induced  H2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells

(2010) L. H. Wang et al.   CLINICAL CANCER RESEARCH

Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors

(2010) A. Mukhopadhyay et al.   CLINICAL CANCER RESEARCH

PARP inhibition: targeting the Achillesʼ heel of DNA repair to treat germline and sporadic ovarian cancers

(2010) Craig P Carden et al.   CURRENT OPINION IN ONCOLOGY

Gene Expression Profile ofBRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer

(2010) Panagiotis A. Konstantinopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer

(2010) Bryan T.J. Hennessy et al.   JOURNAL OF CLINICAL ONCOLOGY

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval

(2010) Peter C. Fong et al.   JOURNAL OF CLINICAL ONCOLOGY

Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic

(2010) Dana V. Ferraris   JOURNAL OF MEDICINAL CHEMISTRY

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

PARP inhibition in BRCA-mutated breast and ovarian cancers

(2010) Stephen L Chan et al.   LANCET

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors

(2010) C. T. Williamson et al.   MOLECULAR CANCER THERAPEUTICS

Susceptibility Pathways in Fanconi's Anemia and Breast Cancer

(2010) Alan D. D'Andrea   NEW ENGLAND JOURNAL OF MEDICINE

Loss of poly(ADP-ribose) polymerase-2 leads to rapid development of spontaneous T-cell lymphomas in p53-deficient mice

(2010) L Nicolás et al.   ONCOGENE

Germ-Line Mutations in Mismatch Repair Genes Associated with Prostate Cancer

(2009) E. M. Grindedal et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

A Phase IB Trial of Intravenous INO-1001 Plus Oral Temozolomide in Subjects with Unresectable Stage-III or IV Melanoma

(2009) Agop Y. Bedikian et al.   CANCER INVESTIGATION

Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2-Mutated Ovarian Carcinoma

(2009) W. Sakai et al.   CANCER RESEARCH

 H2AX Expression in Tumors Exposed to Cisplatin and Fractionated Irradiation

(2009) C. A. Banuelos et al.   CLINICAL CANCER RESEARCH

Coordination of DNA Mismatch Repair and Base Excision Repair Processing of Chemotherapy and Radiation Damage for Targeting Resistant Cancers

(2009) T. J. Kinsella   CLINICAL CANCER RESEARCH

Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?

(2009) Craig P. Carden et al.   DRUG DISCOVERY TODAY

PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination

(2009) Helen E Bryant et al.   EMBO JOURNAL

Synthetic lethal targeting ofPTENmutant cells with PARP inhibitors

(2009) Ana M. Mendes-Pereira et al.   EMBO Molecular Medicine

Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective

(2009) Shahneen K. Sandhu et al.   EUROPEAN JOURNAL OF CANCER

Promising novel therapies for the treatment of endometrial cancer

(2009) Paola A. Gehrig et al.   GYNECOLOGIC ONCOLOGY

Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies

(2009) Shivaani Kummar et al.   JOURNAL OF CLINICAL ONCOLOGY

Utility of DNA Repair Protein Foci for the Detection of Putative BRCA1 Pathway Defects in Breast Cancer Biopsies

(2009) H. Willers et al.   MOLECULAR CANCER RESEARCH

Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity

(2009) A. Choudhury et al.   MOLECULAR CANCER THERAPEUTICS

Disorders of nucleotide excision repair: the genetic and molecular basis of heterogeneity

(2009) James E. Cleaver et al.   NATURE REVIEWS GENETICS

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells

(2009) Y. Zong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Platinum-based chemotherapy in triple-negative breast cancer

(2008) B. Sirohi et al.   ANNALS OF ONCOLOGY

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

(2008) Joshua Z Press et al.   BMC CANCER

BRCA1 promoter methylation is associated with increased mortality among women with breast cancer

(2008) Xinran Xu et al.   BREAST CANCER RESEARCH AND TREATMENT

Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH

(2008) Simon A. Joosse et al.   BREAST CANCER RESEARCH AND TREATMENT

Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum Resistance

(2008) E. M. Swisher et al.   CANCER RESEARCH

Base excision repair of oxidative DNA damage and association with cancer and aging

(2008) S. Maynard et al.   CARCINOGENESIS

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

(2008) R. Plummer et al.   CLINICAL CANCER RESEARCH

Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises

(2008) Timothy A Yap et al.   CURRENT OPINION IN PHARMACOLOGY

Development of PARP inhibitors in oncology

(2008) Jordi Rodon et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy

(2008) Ji Eun Uhm et al.   INTERNATIONAL JOURNAL OF CANCER

“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations

(2008) David S.P. Tan et al.   JOURNAL OF CLINICAL ONCOLOGY

A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair

(2008) Alan Ashworth   JOURNAL OF CLINICAL ONCOLOGY

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

(2008) Wataru Sakai et al.   NATURE

Resistance to therapy caused by intragenic deletion in BRCA2

(2008) Stacey L. Edwards et al.   NATURE

PTEN: a new guardian of the genome

(2008) Y Yin et al.   ONCOGENE

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

(2008) S. Rottenberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA